Form D · Biotechnology
SEVENTH SENSE BIOSYSTEMS, INC.
Medford, MA · CIK 0001451718
Offering snapshot reported Aug 22, 2018 · SEC filing
- Reported sold
- $18.5M Offering amount: $20.5M
- Investors reported
- 18 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 9, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 22, 2018 | Initial | $18,458,837 | No comparison | 18 | SEC filing |
| Feb 21, 2018 | Initial | $3,459,381 | No comparison | 15 | SEC filing |
| Sep 20, 2017 | Initial | $2,500,000 | No comparison | 2 | SEC filing |
| Nov 16, 2016 | Initial | $5,500,000 | No comparison | 7 | SEC filing |
| Dec 22, 2015 | Initial | $2,060,000 | No comparison | 6 | SEC filing |
| Aug 6, 2015 | Amendment | $14,287,084 | $3,820,000vs Aug 8, 2014 | 8 | SEC filing |
| Aug 8, 2014 | Initial | $10,467,084 | No comparison | 8 | SEC filing |
| Jun 18, 2014 | Initial | $450,000 | No comparison | 5 | SEC filing |
| Apr 10, 2014 | Initial | $930,000 | No comparison | 5 | SEC filing |
| Nov 21, 2013 | Initial | $360,000 | No comparison | 5 | SEC filing |
| Apr 1, 2013 | Initial | $157,500 | No comparison | 1 | SEC filing |
| Mar 18, 2013 | Initial | $1,800,000 | No comparison | 5 | SEC filing |
| Jun 19, 2012 | Amendment | $12,182,963 | $5,499,999vs May 10, 2011 | 6 | SEC filing |
| Jun 1, 2012 | Initial | $200,000 | No comparison | 5 | SEC filing |
| Apr 10, 2012 | Initial | $750,000 | No comparison | 5 | SEC filing |
| May 10, 2011 | Initial | $6,682,964 | No comparison | 6 | SEC filing |
| Oct 14, 2010 | Initial | $2,100,000 | No comparison | 6 | SEC filing |
| Jun 4, 2010 | Initial | $1,500,000 | No comparison | 6 | SEC filing |
| Dec 2, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-319773
Source: Form D, filed Aug 22, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Rox Anderson | Director |
| R. Rox Anderson | Director |
| Howard Bernstein | Executive |
| Stuart Blitz | Executive |
| Marc Ceulemans | Director |
| Don Chickering | Executive |
| Doug Cole | Director |
| Alan Crane | Director |
| Neil Exter | Director |
| Donald Hardison | Director |
| Peter Hutt | Director |
| Milan Kofol | Executive |
| Robert Langer | Director |
| Doug Levinson | Director, Executive |
| Timothy Richards | Executive |
| Anupendra Sharma | Director |
| Amy Siegel | Executive |
| Howard Weisman | Director |
| Harry Wilcox | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
200 Boston Avenue, Suite 3700
Medford, MA, 02155
Medford, MA, 02155